MannKind Corporation Starts New Marketing Campaign for Afrezza (inhaled insulin)

I first wrote about inhaled insulin in 2014. I have yet to run across a patient using it. In fact, I thought it may have been taken off the market for a while. In any case, it’s back:

“MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) announced it is now distributing MannKind-branded Afrezza® (insulin human) Inhalation Powder directly to major wholesalers and that Afrezza is available by prescription from retail pharmacies nationwide.  The MannKind-branded product is associated with new National Drug Code (NDC) numbers, as noted in the table below. With distribution channels now stocked, the Company announced several key programs to promote access, adoption and adherence to Afrezza therapy.”

Source: MannKind Corporation – Mannkind Assumes Responsibility for Distribution of Afrezza® and Launches Patient Reimbursement and Adherence Support Programs